Of the 11,320 patients randomized between 19 March and 8 June, 9355 (83%) were eligible to be randomized to dexamethasone. Of these, 2104 were randomized to dexamethasone and 4321 were randomized to usual care, with the remainder being randomized to one of the other treatment arms. Mean age of study participants in this comparison was 66.1 years and 36% patients were female. A history of diabetes was present in 24% of patients, heart disease in 27%, and chronic lung disease in 21%, with 56% having at least one major comorbidity recorded. In this analysis, 82% of patients had laboratory confirmed SARS-CoV-2 infection, with the result currently awaited for 9%. At randomization, 16% were receiving invasive mechanical ventilation or extracorporeal membrane oxygenation, 60% were receiving oxygen only (with or without non-invasive ventilation), and 24% were receiving neither.